Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

We analysed whole-genome sequences of 560 breast cancers to advance understanding of
the driver mutations conferring clonal advantage and the mutational processes generating …

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

We analysed primary breast cancers by genomic DNA copy number arrays, DNA
methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and …

Cellular mitophagy means that cells selectively wrap and degrade damaged mitochondria
through an autophagy mechanism, thus maintaining mitochondria and intracellular …

The genomic landscape of breast cancer is complex, and inter-and intra-tumour
heterogeneity are important challenges in treating the disease. In this study, we sequence …

Although p53 inactivation promotes genomic instability and presents a route to malignancy
for more than half of all human cancers,, the patterns through which heterogenous TP53 …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …